MedTrace Logo

Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention

NCT01796873 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2024-08-22

No results posted yet for this study

Summary

Plavix (clopidogrel) is a drug that is approved by the FDA (Food and Drug Administration) to reduce the risk of having another heart attack by preventing platelets (blood cells that are important in forming blood clots) from sticking together and forming another clot. Platelet activity can be measured by a machine called VerifyNow.

The purpose of this study is to see whether Hispanic women and White non-Hispanic women have the same platelet response to a commonly used drug, Plavix (clopidogrel). Recent studies have shown that platelets may be more active in Hispanics, making it more difficult to prevent clots from forming, even when using Plavix. In addition, studies have shown that women may also have more active platelets than men. There have been no studies of Hispanic women and the effect of Plavix on platelet activity.

Conditions

Sponsors & Collaborators

  • University of Arizona

    lead OTHER

Principal Investigators

  • Sasanka Jayasuriya, MD · University of Arizona

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-01-31
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01796873 on ClinicalTrials.gov